| |
|
|
|
|
| November 5 ,
2009 | ISSUE NUMBER 123 VOL 6 |
Deals
Glaxo Vies for a Second Act in HIV
A novel joint venture between Glaxo and Pfizer is big on promise. But the combined portfolio and pipeline of HIV drugs? Not so much.
Stategy
J&J Cuts Staff in Major Restructuring Move
Johnson & Johnson announced a massive restructuring plan on Tuesday in an effort to save $1.4 billion to $1.7 billion by 2011. The human cost: 7 percent of its workforce.
Marketing
Pfizer Quietly Updates Company Logo
Pfizer’s blue oval logo has been its icon for years, so it was a bit of a surprise when the company modified the brand ever so slightly in the past few weeks.
New Media
AZ’s First Corporate Blog Falls Flat
AstraZeneca Health Connections does little to create a dialogue with patients or businesses. Are the FDA’s dated restrictions on social media doing more harm than good?
Sales
A Lead Drug on the Way? All Eyes on FDA
For a small company like NeurogesX, FDA action on its lead drug Qutenza is, in many ways, a make-or-break moment. Anthony DiTonno, CEO of NeurogesX, shares the company's marketing/sales rollout plan.
Podcast
If Emerging Pharma Leadership Awards – Michelle Dipp
“The current economic environment is forcing the industry to adapt and change for the better in order to survive. I believe this will result in survival of the fittest, and biotech will be a source of pride and innovation in the US for decades to come.” Listen to the Podcast for more coverage.
New & Noteworthy
Innovation Over Imitation
As the first generation of biologics patents expire, companies are jockeying for position in follow-on biologics. |
Advertisement:
CBI’s 8th Annual Commercialization Strategies for Pharmaceutical Product Launches – December 8–9, 2009, Philadelphia, PA
Leverage Successful Product Planning, Marketing, Pricing and Reimbursement Strategies for Accelerated Product Uptake
Save $400 off of your registration fee!* Mention promotional code QDD993 when registering.
Call 800-817-8601 or visit
 www.cbinet.com/ProductLaunchEast
*Discount offer can not be combined with other discounts or applied to a current registration.
Offer not valid on workshop only or academic registrations.
|
 |
|  Noble Marketing made Barbara Perkalis vice president of business development
// ProCom, a CommonHealth medical-education unit, hired George Davatelis, M.D., senior medical director and Erica Ray account director
// BMP Sunstone appointed Daniel P. Harrington to its board of directors
//AbelsonTaylor hired Kristin Glunz senior account supervisor and Tony Malik as account supervisor
// The board of directors for Shire added David Stout as a non-executive director
// Watson Pharmaceuticals named R. Todd Joyce senior vice president and chief financial officer
// Ferring Pharmaceuticals appointed Harry F. Kovelman, M.D., associate medical director for orthopedics
// Qforma appointed Erin McLaughlin to director of field operations
// Vivus promoted Peter Tam to president
// Laureate Pharma made Andrew Arrage and Patricia Caplan director, business development–East; and Bruce Frazier manager, business development–West
// Kendle appointed J. Michael Sprafka vice president
//
|
December 2 Risk, Reward and the Pharmaceutical Life Cycle: Managing Information as a Strategic Productivity Asset
Wednesday, December 2, 2009 at 11AM ET
|
Nov 9–10, 2009 Annual Defining Appropriate and Effective Interactions with Thought Leaders and Key Opinion Leaders,
Princeton, NJ
Nov 17–18, 2009 3rd Annual Evidence-Based Medicine and Comparative Effectiveness Research Summit for the Bio/Pharmaceutical and Medical Device Industries,
Philadelphia, PA
Dec 8–9, 2009 Forum on FDA’s Structured Product Labeling, Washington, DC
Jan 21–22, 2010 Bio/Pharmaceutical Forum on Optimizing the Use of Complex Data Assets,
Philadelphia, PA
Jan 25–26, 2010 Bio/Pharmaceutical Forum on Strategic Sourcing and Procurement,
Philadelphia, PA
Feb 8–9, 2010 3rd Annual Clinical Trial Forecasting and Budgeting, Philadelphia, PA |
|
|
|
 |
|
 |
|
 |
| Is your pharmaceutical company planning on upgrading its operating system in the next year? |
|
|
|
|
You are subscribed to Pharm Exec Direct..
To unsubscribe,
click here
To ensure delivery to your Inbox, please add us to your address book. If you need help doing this, click here.
Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.
|
|
